MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme Operating Cycle 2011-2025 | EPZM
Annual Operating Cycle Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 47.2 | 834 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 834 | 47.2 | 441 |
Quarterly Operating Cycle Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 28.4 | 65.5 | - | 151 | 78.9 | 244 | 296 | 376 | 582 | 191 | 54.5 | 41 | 39.7 | 131 | 189 | 153 | 153 | - | - | 3.49 | 3.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 582 | 3.49 | 154 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
195 | $ 25.33 | -2.2 % | $ 1.23 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.71 | 0.86 % | $ 782 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.31 | -1.64 % | $ 256 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
4.89 | $ 1.3 | -2.26 % | $ 7.09 M |  China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Anika Therapeutics
ANIK
|
325 | $ 9.53 | 0.42 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
349 | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
360 | $ 2.32 | 1.75 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
AstraZeneca PLC
AZN
|
206 | $ 89.4 | -0.99 % | $ 96.9 B | Britain |
 |
Baudax Bio
BXRX
|
126 | - | 0.59 % | $ 63 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
114 | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
116 | $ 570.03 | -1.89 % | $ 43.2 B | USA |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
452 | $ 173.43 | 0.54 % | $ 25.3 B | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
2.1 K | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
408 | $ 11.38 | -0.52 % | $ 736 M | USA |
 |
Benitec Biopharma
BNTC
|
141 | $ 12.27 | -5.32 % | $ 505 M | USA |
 |
Catalyst Biosciences
CBIO
|
410 | $ 14.5 | -5.29 % | $ 955 M | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Cerus Corporation
CERS
|
59.2 | $ 2.13 | -0.7 % | $ 393 M | USA |